Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (ALS)

Angel Porgador; Rachel Lichtenstein

Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (ALS)

Angel Porgador (Inventor), Rachel Lichtenstein (Inventor)

Research output: Patent

Abstract

The present invention provides a method of treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject, the method comprising administering to a subject an agent, which interferes with IgG-A2BG2 expression, IgG-A2BG2 function or IgG-A2BG2 interaction with CD16 in said subject.

Original language	American English
Patent number	US9861686B2
State	Published - 1 Jan 2018

Cite this

@misc{d5a406bb477f4c3299696f6e27da73df,

title = "Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (ALS)",

abstract = "The present invention provides a method of treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject, the method comprising administering to a subject an agent, which interferes with IgG-A2BG2 expression, IgG-A2BG2 function or IgG-A2BG2 interaction with CD16 in said subject.",

author = "Angel Porgador and Rachel Lichtenstein",

note = "US Patent 9,861,686; US9861686B2",

year = "2018",

month = jan,

day = "1",

language = "American English",

type = "Patent",

}

TY - PAT

T1 - Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (ALS)

AU - Porgador, Angel

AU - Lichtenstein, Rachel

N1 - US Patent 9,861,686

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The present invention provides a method of treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject, the method comprising administering to a subject an agent, which interferes with IgG-A2BG2 expression, IgG-A2BG2 function or IgG-A2BG2 interaction with CD16 in said subject.

AB - The present invention provides a method of treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject, the method comprising administering to a subject an agent, which interferes with IgG-A2BG2 expression, IgG-A2BG2 function or IgG-A2BG2 interaction with CD16 in said subject.

M3 - Patent

M1 - US9861686B2

ER -

Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (ALS)

Abstract

Fingerprint

Cite this